despit
continu
effort
optim
vaccin
composit
sever
influenza
diseas
requir
intens
care
unit
icu
admiss
remain
clinic
issu
influenza
epidem
pandem
worldwid
continu
challeng
clinician
manag
infect
patient
requir
icu
care
routin
use
antivir
therapi
deploy
ambulatori
outpati
use
icu
patient
hypoxem
respiratori
failur
less
well
establish
addit
therapi
primarili
target
neuraminidas
protein
contemporari
research
increasingli
demonstr
potenti
therapeut
benefit
target
hemagglutinin
protein
data
given
rise
grow
interest
use
immun
modul
therapi
treatment
sever
influenza
addit
pandem
outbreak
reveal
grow
need
salvag
manag
wherein
lie
potenti
role
venoven
extracorpor
membran
oxygen
therapi
refractori
respiratori
failur
report
review
contemporari
icu
care
sever
influenza
patient
epidem
influenza
occur
annual
unit
state
typic
late
fall
earli
spring
surveil
data
suggest
influenza
respons
nearli
three
quarter
million
hospit
intens
care
unit
icu
admiss
death
annual
children
two
year
age
adult
age
year
highest
risk
advers
outcom
addit
presenc
chronic
medic
condit
immunosuppress
pregnanc
obes
may
also
increas
risk
advers
outcom
predomin
season
influenza
viru
subtyp
circul
sinc
howev
sinc
influenza
pandem
predomin
season
influenza
viru
strain
strain
result
increas
diseas
sever
relat
influenza
infect
influenza
viru
result
bronchial
hyperreact
distal
airway
obstruct
impair
diffus
capac
sever
alveolar
inflamm
factor
lead
respiratori
compromis
sever
case
need
icu
admiss
endotrach
tube
placement
facilit
mechan
ventil
center
diseas
control
prevent
cdc
recommend
antivir
treatment
soon
possibl
patient
confirm
suspect
influenza
sever
complic
progress
ill
requir
hospit
oseltamivir
zanamavir
recommend
base
data
indic
circul
strain
sensit
medic
sporad
oseltamivirresist
viru
infect
identifi
howev
known
impact
limit
articl
review
approv
experiment
therapi
adult
patient
hospit
intens
care
unit
sever
influenza
popul
high
risk
dismal
outcom
inhibitor
neuraminidas
surfac
glycoprotein
oseltamivir
cornerston
influenza
treatment
metaanalysi
random
trial
support
use
oseltamivir
shorten
time
symptom
allevi
reduc
occurr
lower
respiratori
tract
infect
admitt
hospit
consequ
higher
risk
nausea
vomit
furthermor
earli
oseltamivir
use
may
reduc
durat
hospit
patient
influenza
random
trial
use
efficaci
oseltamivir
conduct
patient
sever
ill
wherein
mortal
would
rare
therefor
evid
limit
evalu
impact
oseltamivir
mortal
import
endpoint
critic
ill
patient
use
oseltamivir
patient
popul
base
larg
observ
report
mani
recent
analys
evalu
impact
oseltamivir
influenza
caus
pandem
strain
impact
earli
administr
oseltamivir
evalu
prospect
observ
studi
adult
patient
admit
icu
microbiolog
confirm
infect
influenza
season
spain
author
compar
patient
receiv
earli
oseltamivir
treatment
within
day
symptom
onset
receiv
oseltamivir
day
symptom
onset
effect
earli
oseltamivir
evalu
propens
score
creat
use
covari
determin
among
baselin
differ
group
studi
evalu
patient
mean
age
year
mean
apach
ii
score
day
patient
requir
invas
mechan
ventil
entir
popul
receiv
earli
oseltamivir
half
patient
receiv
oseltamivir
mg
day
icu
admiss
entir
patient
popul
nonsignific
differ
icu
mortal
receiv
earli
vs
late
oseltamivr
ci
howev
subset
patient
n
invas
ventil
receiv
effect
treatment
defin
receiv
dose
antivir
therapi
icu
mortal
receiv
late
oseltamivir
receiv
earli
oseltamivir
ci
correspond
rel
risk
receiv
earli
oseltamivir
ci
multivari
analys
confirm
associ
earli
oseltamivir
improv
surviv
death
ci
subset
ventil
patient
author
conclud
earli
administr
oseltamivir
associ
improv
surviv
ventil
patient
influenza
metaanalysi
individu
patient
data
multipl
data
set
sought
evalu
efficaci
neuraminidas
inhibitor
nai
hospit
patient
influenza
pandem
primari
outcom
mortal
hospit
admiss
individu
studi
followup
period
author
evalu
effect
oseltamivir
variou
subgroup
patient
treatment
vs
none
earli
within
day
symptom
onset
vs
late
treatment
earli
treatment
vs
none
late
treatment
vs
none
author
abl
use
patient
differ
data
set
analysi
mortal
rate
patient
critic
ill
adult
defin
admiss
critic
care
unit
mortal
rate
patient
popul
neuraminidas
inhibitor
administ
patient
entir
popul
oral
oseltamivir
use
patient
outcom
adjust
treatment
propens
corticosteroid
use
antibiot
use
among
critic
ill
adult
nai
use
associ
mortal
reduct
compar
therapi
ci
earli
nai
use
associ
reduct
mortal
compar
late
therapi
ci
critic
ill
patient
mortal
reduct
also
statist
signific
critic
ill
patient
receiv
nai
versu
therapi
treat
earlier
ci
later
ci
studi
limit
inabl
control
diseas
sever
baselin
howev
larg
dataset
provid
evid
use
nai
associ
reduc
mortal
critic
ill
patient
data
would
support
oseltamivir
associ
reduct
mortal
use
earli
patient
pandem
influenza
howev
even
use
earli
late
oseltamivir
use
may
also
associ
reduct
mortal
median
time
symptom
onset
late
oseltamivir
day
studi
rodriguez
et
al
day
studi
muthuri
et
al
effect
oseltamivir
patient
present
outsid
window
entir
clear
mani
limit
interpret
data
critic
ill
patient
includ
lack
standard
definit
critic
ill
patient
lack
evalu
differ
outcom
without
histori
underli
pulmonari
diseas
concomit
bacteri
pneumonia
associ
increas
morbid
furthermor
unclear
whether
potenti
benefit
nai
seen
studi
would
also
appli
patient
nonpandem
strain
influenza
whether
benefit
would
seen
vaccin
vs
unvaccin
patient
import
prior
studi
demonstr
influenza
vaccin
may
protect
secondari
pneumonia
may
depend
upon
circul
influenza
strain
oseltamivir
gener
welltoler
howev
neuropsychiatr
event
delirium
hallucin
behavior
chang
rare
dermatolog
reaction
eg
toxic
epiderm
necrolysi
stevensjohnson
syndrom
report
may
discourag
use
critic
ill
patient
interest
use
dose
oseltamivir
higher
standard
recommend
mg
twice
daili
dose
interest
born
concern
regard
absorpt
oseltamivir
critic
ill
patient
perhap
improv
efficaci
higher
dose
pharmacokinet
studi
sought
evalu
plasma
concentr
oseltamivir
administ
oral
via
nasogastr
tube
critic
ill
patient
serum
level
oseltamivir
free
base
carboxyl
metabolit
measur
baselin
h
fourth
oseltamivir
dose
later
includ
patient
receiv
enter
nutrit
vasopressor
therapi
author
found
serum
concentr
activ
oseltamivir
carboxyl
metabolit
similar
level
seen
ambulatori
patient
therefor
like
trough
concentr
theoriz
pharmacodynam
threshold
maxim
inhibit
viru
though
author
report
valu
furthermor
correl
bodi
weight
area
curv
volum
distribut
suggest
dose
adjust
requir
obes
retrospect
cohort
studi
critic
ill
patient
receiv
either
highdos
mgday
standard
dose
mgday
oseltamivir
base
renal
adjust
daili
dose
evalu
impact
icufre
day
patient
receiv
higher
dose
n
younger
vs
year
higher
sofa
score
day
therapi
vs
higher
fraction
inspir
oxygen
day
therapi
vs
like
influenza
vs
baselin
characterist
use
therapi
vasoact
medic
antibiot
similar
group
patient
receiv
high
dose
oseltamivir
fewer
icu
free
day
vs
p
ventilatorfre
day
vs
p
b
higher
mortal
vs
p
b
multivari
analys
highdos
oseltamivir
independ
associ
mortal
time
icu
discharg
studi
support
differ
clinic
outcom
highdos
oseltamivir
random
control
trial
conduct
indonesia
singapor
thailand
vietnam
compar
doubl
dose
oseltamivir
mg
twice
daili
standard
dose
oseltamivir
mg
twice
daili
primari
endpoint
absenc
viral
rna
combin
nasal
throat
swab
day
studi
includ
pediatr
adult
patient
dose
oseltamivir
adjust
weigh
kg
patient
receiv
five
day
oseltamivir
meet
criteria
clinic
failur
day
receiv
addit
five
day
therapi
major
enrol
patient
children
median
age
year
influenza
present
patient
season
icu
admiss
requir
patient
requir
mechan
ventil
day
five
proport
patient
neg
viral
rna
similar
doubl
dose
standard
dose
group
p
doubl
dose
standard
dose
group
also
differ
clinic
failur
day
vs
p
mortal
vs
p
major
death
patient
avian
viru
studi
support
differ
clinic
virolog
outcom
higher
dose
oseltamivir
use
although
result
primarili
appli
pediatr
popul
limit
data
exist
regard
absorpt
oseltamivir
drug
concentr
critic
ill
patient
one
pharmacokinet
studi
suggest
drug
concentr
obtain
critic
ill
patient
differ
ambulatori
patient
describ
furthermor
evid
suggest
differ
clinic
outcom
base
oseltamivir
dose
oseltamivir
mg
oral
twice
daili
adjust
renal
function
may
use
major
critic
ill
patient
unless
signific
malabsorpt
known
suspect
given
diseas
sever
associ
influenzarel
ill
encount
icu
mani
patient
may
eventu
requir
renal
replac
therapi
extracorpor
membran
oxygen
ecmo
prospect
pharmacokinet
studi
patient
either
continu
venoven
hemodiafiltr
cvvhd
ecmo
evalu
pharmacokinet
paramet
plasma
concentr
oseltamivir
patient
patient
studi
receiv
oseltamivir
mg
twice
daili
serum
sampl
obtain
regular
interv
follow
drug
administr
hemodialyz
cvvhd
directli
oxygen
ecmo
cvvhd
contribut
significantli
clearanc
oseltamivir
carboxyl
preand
postoxygen
concentr
oseltamivir
oseltamivir
carboxyl
differ
author
found
higher
oseltamivir
carboxyl
area
curv
dose
interv
auc
would
expect
noncrit
ill
patient
receiv
dosag
regimen
dose
util
result
higher
median
auc
level
would
expect
noncrit
ill
patient
receiv
regimen
author
state
mg
twice
daili
dose
oseltamivir
would
reason
patient
cvvhd
similar
effluent
rate
use
analysi
mlh
furthermor
auc
lower
patient
receiv
cvvhd
ecmo
compar
patient
receiv
cvvhd
studi
popul
may
small
draw
firm
conclus
regard
oseltamivir
dose
ecmo
howev
author
specul
higher
dose
may
requir
patient
particularli
gastrointestin
dysfunct
may
present
oseltamivir
durat
therapi
beyond
five
day
formal
evalu
recommend
clinic
expert
pandem
world
health
organ
recommend
antivir
therapi
maintain
satisfactori
clinic
improv
cdc
echo
recommend
prolong
therapi
patient
sever
state
continu
beyond
five
day
prolong
viral
shed
note
present
beyond
day
hospit
patient
influenza
given
lack
clinic
data
may
reason
extend
durat
oseltamivir
beyond
five
day
patient
sever
influenza
delay
clinic
respons
altern
readili
avail
antivir
drug
suscept
test
may
consid
fda
commission
order
emerg
use
author
eua
intraven
peramivir
influenza
season
drug
could
access
hospit
patient
suspect
confirm
influenza
peramivir
receiv
approv
fda
approv
base
multin
multicent
doubleblind
doubledummi
random
control
studi
patient
receiv
singl
intraven
infus
peramivir
mg
oral
oseltamivir
mg
twice
daili
day
studi
peramivir
found
noninferior
oseltamivir
regard
allevi
influenza
symptom
follow
eua
intraven
peramivir
initi
evalu
patient
receiv
therapi
demonstr
drug
well
toler
associ
recoveri
patient
rash
treatmentrel
advers
effect
attribut
peramivir
analysi
report
submit
fda
advers
event
report
system
analysi
hospit
icu
patient
california
sought
describ
epidemiolog
clinic
characterist
outcom
patient
receiv
iv
peramivir
epidem
case
patient
hospit
icu
h
acut
respiratori
infect
laboratori
evid
infect
reversetranscriptas
polymeras
chain
reaction
compar
analysi
perform
critic
ill
patient
treat
nai
receiv
peramivir
patient
receiv
treatment
nai
receiv
iv
peramivir
patient
mechan
ventil
suspect
bacteri
coinfect
major
case
receiv
concurr
second
antivir
commonli
oseltamivir
time
symptom
onset
treatment
oral
nai
day
symptom
onset
peramivir
day
common
reason
initi
peramivir
respond
oral
inhal
antivir
suspect
malabsorpt
twentynin
patient
receiv
peramivir
die
patient
die
receiv
peramivir
like
diagnos
acut
renal
failur
p
shorter
length
hospit
stay
vs
day
p
receiv
peramivir
shorter
durat
vs
day
p
compar
survivor
receiv
peramivir
patient
receiv
peramivir
compar
case
icu
treat
nai
peramivir
patient
treat
peramivir
higher
rate
obes
morbid
obes
like
diagnos
pneumoniaacut
respiratori
distress
syndrom
ard
p
sepsi
p
b
requir
mechan
ventil
p
b
die
p
b
author
question
safeti
effect
peramivir
hospit
critic
ill
patient
highlight
need
larg
random
control
trial
area
singleinstitut
retrospect
review
conduct
korea
sought
compar
efficaci
peramivir
oseltamivir
critic
ill
patient
season
influenza
critic
ill
patient
defin
admit
icu
requir
mechan
ventil
pao
fio
ratio
b
requir
infus
inotrop
vasoact
medic
patient
divid
two
group
base
initi
treatment
either
peramivir
n
oseltamivir
n
averag
age
year
male
baselin
patient
receiv
peramivir
higher
sofa
score
vs
higher
proport
patient
shock
vs
patient
receiv
oseltamivir
like
chronic
heart
diseas
vs
influenza
predomin
group
peramivir
group
oseltamivir
group
peramivir
chang
oseltamivir
patient
primarili
due
clinic
improv
icu
oseltamivir
chang
peramivir
patient
eleven
patient
progress
pneumonia
half
patient
treat
peramivir
receiv
mg
dose
oseltamivir
patient
receiv
mg
dose
median
durat
antivir
therapi
day
peramivir
group
day
oseltamivir
group
peramivir
oseltamivir
group
differ
icu
mortal
vs
p
inhospit
mortal
vs
p
icu
hospit
length
stay
multivari
analysi
increas
age
associ
mortal
peramivir
use
author
conclud
critic
ill
patient
sever
influenza
treat
either
intraven
peramivir
enter
oseltamivir
depend
appropri
rout
administr
differ
outcom
although
studi
may
lack
adequ
power
detect
differ
outcom
caseseri
taiwan
describ
use
salvag
peramivir
critic
ill
patient
initi
receiv
oseltamivir
peramivir
time
symptom
onset
oseltamivir
day
time
onset
peramivir
day
differ
survivor
nonsurvivor
time
receipt
either
oseltamivir
peramivir
overal
surviv
adult
patient
multivari
logist
regress
analysi
adult
patient
lower
bodi
weight
complic
bacteremia
acut
renal
injuri
higher
steroid
use
independ
predictor
mortal
author
recommend
studi
evalu
safeti
efficaci
peramivir
studi
need
critic
ill
patient
evalu
efficaci
peramivir
time
lack
compel
evid
recommend
peramivir
oseltamivir
howev
may
consid
patient
unabl
receiv
oral
oseltamivir
oseltamivir
neuropsychiatr
rare
dermatolog
reaction
may
occur
data
use
zanamivir
critic
ill
patient
much
limit
oseltamivir
peramivir
approv
formul
zanamivir
inhal
dri
power
deliv
via
diskhal
devic
aerosol
zanamivir
recommend
critic
ill
patient
mechan
ventil
may
clog
ventil
circuit
intraven
zanamivir
investig
product
avail
via
enrol
clinic
trial
investig
new
drug
request
strain
influenza
season
show
suscept
oseltamivir
peramivir
howev
strain
suscept
zanamivir
zanamivir
appear
maintain
activ
oseltamivirresist
peramivirresist
influenza
strain
limit
data
guid
use
iv
zanamivir
critic
ill
patient
intern
phase
iii
studi
intraven
zanamiavir
hospit
patient
influenza
compar
intraven
zanamivir
mg
mg
oral
oseltamivir
baselin
approxim
patient
icu
requir
endotrach
intub
half
patient
receiv
prior
treatment
oseltamivir
differ
time
clinic
respons
entir
popul
popul
patient
admit
icu
case
report
case
seri
describ
use
intraven
zanamivir
critic
ill
patient
report
describ
use
intraven
zanamivir
critic
ill
patient
diseas
progress
despit
oseltamivir
use
zanamivir
led
clinic
success
major
patient
howev
difficult
draw
firm
conclus
limit
data
may
reason
use
intraven
zanamivir
fda
investig
new
drug
request
process
patient
confirm
suspect
oseltamivirresist
peramivirresist
strain
data
regard
use
adamantan
antivir
agentstarget
protein
ion
channelar
restrict
noncrit
ill
popul
monotherapi
agent
larg
fallen
favor
given
high
propens
resist
howev
limit
data
evalu
amantadin
part
tripl
drug
therapi
approach
kim
et
al
retrospect
analyz
cohort
patient
requir
mechan
ventil
pandem
korea
twenti
four
patient
receiv
treatment
combin
oseltamivir
mg
twice
daili
amantadin
mg
twice
daili
ribavirin
mg
thrice
daili
receiv
oseltamivir
monotherapi
signific
advers
safeti
concern
author
found
tripl
antivir
therapi
reduc
mortal
overal
outcom
similar
receiv
oseltamivir
monotherapi
virolog
endpoint
assess
studi
doubleblind
fashion
beigel
et
al
random
patient
receiv
tripl
therapi
oseltamivir
mg
twice
daili
amantadin
mg
twice
daili
ribavirin
mg
twice
daili
oseltamivir
monotherapi
author
found
greater
viral
clearanc
tripl
therapi
clinic
endpoint
includ
resolut
symptom
differ
monotherapi
unfortun
author
report
mani
person
requir
icu
admiss
mechan
ventil
limit
abil
extrapol
data
critic
ill
popul
histor
influenza
pandem
serv
backbon
research
advanc
manag
sever
influenza
diseas
kobasa
colleagu
use
revers
genet
synthes
hemagglutinin
ha
neuraminidas
na
gene
present
influenza
viru
respons
spanish
influenza
pandem
infect
three
differ
mous
model
one
wildtyp
viru
one
engin
ha
na
gene
one
ha
gene
wildtyp
model
experienc
mild
diseas
minim
patholog
chang
mutant
model
manifest
diffus
pulmonari
diseas
massiv
cytokin
surg
alveolar
hemorrhag
patholog
chang
present
model
irrespect
neuraminidas
chang
author
suggest
mutat
hemagglutinin
gene
alon
primari
driver
virul
viru
sever
mechan
benefit
immun
modul
therapi
sever
influenza
diseas
propos
antiinfluenza
antibodi
may
inhibit
bind
viru
sialic
acid
receptor
epitheli
cell
line
respiratori
tract
inhibit
proteas
activ
hemagglutinin
inhibit
viral
fusion
epitheli
cell
subsequ
intern
viru
prevent
releas
progeni
virion
host
cell
use
convalesc
blood
product
infecti
diseas
date
back
wherein
use
routin
treatment
prevent
bacteri
viral
infect
use
taper
discoveri
widespread
use
antimicrobi
agent
earlymid
convalesc
product
continu
use
today
sever
viral
ill
lack
vaccin
medic
specif
therapi
due
ebola
viru
diseas
middl
east
respiratori
syndrom
coronaviru
sar
coronaviru
other
observ
experi
spanish
influenza
pandem
found
mortal
benefit
use
convalesc
plasma
particularli
administ
earli
cours
ill
modern
era
convalesc
plasma
first
administ
otherwis
healthi
middleag
male
guangdong
provinc
china
respond
standard
oseltamivir
therapi
plasma
collect
patient
suffer
influenza
diseas
anhui
provinc
earlier
year
hemagglutinin
gene
two
virus
share
near
complet
homolog
shortli
administr
patient
viral
load
decreas
precipit
undetect
level
fever
resolv
case
suggest
convalesc
product
need
collect
patient
suffer
exact
strain
influenza
viru
may
benefici
commerci
use
prospect
cohort
studi
patient
pandem
evalu
deterior
despit
optim
antivir
treatment
requir
icu
admiss
within
day
symptom
onset
twenti
patient
receiv
treatment
convalesc
plasma
nearli
patient
requir
mechan
ventil
almost
half
receiv
stress
dose
steroid
approxim
oneeighth
place
ecmo
multivari
analysi
reveal
treatment
convalesc
plasma
independ
associ
surviv
dead
vs
aliv
p
addit
viral
load
inflammatori
marker
includ
decreas
higher
rate
receiv
convalesc
plasma
first
random
control
trial
convalesc
plasma
enrol
patient
sever
influenza
diseas
defin
hypoxia
arteri
oxygen
satur
b
tachypnea
respiratori
rate
n
bpm
approxim
onehalf
entir
cohort
infect
third
patient
random
receiv
convalesc
plasma
convalesc
plasma
group
receiv
standard
care
includ
antivir
therapi
commonli
oseltamivir
nearli
includ
patient
requir
oxygen
administr
form
onethird
diagnos
acut
respiratori
distress
syndrom
half
requir
icu
admiss
differ
primari
outcom
group
normal
respiratori
statu
subgroup
analysi
reveal
signific
benefit
patient
receiv
plasma
within
day
p
differ
found
icu
admiss
icu
hospit
length
stay
need
mechan
ventil
supplement
oxygen
advers
event
studi
howev
underpow
unblind
may
led
higher
rate
lack
followup
among
random
standard
care
arm
group
receiv
nai
thu
true
effect
convalesc
plasma
influenza
diseas
remain
unknown
variabl
hemagglutinin
inhibit
titer
among
plasma
administ
effect
dose
remain
unknown
address
mani
limit
phase
iii
doubleblind
random
trial
highv
lowtit
convalesc
plasma
sever
influenza
diseas
current
ongo
safeti
consider
use
convalesc
plasma
includ
expect
administr
blood
product
transfusionrel
reaction
transfusionrel
lung
injuri
antibodydepend
enhanc
blood
born
infect
thromboembol
diseas
addit
due
higher
volum
load
patient
may
toler
plasma
infus
creat
pool
sera
thousand
donor
intraven
immunoglobulin
ivig
origin
thought
contain
antiinfluenza
antibodi
addit
studi
suggest
igg
benefit
ivig
beyond
specif
antiinfluenza
antibodi
includ
ivig
contain
larg
amount
carbohydratebind
antibodi
may
shield
sialic
acid
bind
site
respiratori
epitheli
cell
sialyl
portion
serv
decoy
influenza
viral
bind
experi
ivig
influenza
diseas
limit
case
report
otherwis
healthi
male
necessit
mechan
ventil
pandem
despit
highdos
oseltamivir
therapi
ventilatori
requir
continu
increas
thu
ivig
administ
dosag
mgkg
daili
day
approxim
week
follow
first
dose
ivig
abl
liber
ventil
analysi
commerci
avail
ivig
product
reveal
increas
ha
microneutr
titer
increas
ivig
concentr
author
found
administr
high
dose
ivig
gkg
serum
titer
microneutr
ha
significantli
increas
caution
execut
data
howev
level
hemagglutinin
inhibit
present
commerci
avail
ivig
product
may
depend
geograph
locat
demograph
patient
select
serum
donor
due
shortcom
ivig
hyperimmun
globulin
hivig
creat
fraction
convalesc
blood
productsi
propos
confer
igg
benefit
ivig
ad
specif
antiinfluenza
antibodi
insight
flu
group
perform
pharmacokinet
analysi
ha
inhibit
evolut
hivig
administr
hivig
patient
activ
influenza
diseas
mainli
influenza
b
serum
ha
inhibit
titer
significantli
increas
least
three
day
earlier
patient
administ
placebo
undergo
natur
cours
infect
random
doubleblind
trial
evalu
patient
deterior
despit
standard
antivir
treatment
requir
icu
admiss
posit
pressur
ventil
within
day
symptom
onset
patient
random
receiv
hivig
mgkg
ivig
mgkg
ivig
screen
use
requir
low
level
ha
inhibit
titer
nearli
includ
patient
requir
mechan
ventil
third
place
ecmo
viral
load
significantli
reduc
day
hivig
recipi
administ
within
day
symptom
onset
hivig
confer
significantli
greater
surviv
benefit
ivig
recipi
p
studi
limit
small
sampl
size
high
number
exclud
patient
late
icu
admiss
long
term
outcom
ideal
dosag
hivig
remain
unknown
address
mani
limit
quadrupleblind
random
trial
hivig
without
standard
antivir
therapi
sever
influenza
diseas
current
ongo
safeti
consider
ivig
hivig
must
extrapol
use
indic
due
lack
avail
data
influenza
diseas
advers
event
includ
expect
immunoglobulin
administr
infusionrel
reaction
acut
kidney
injuri
thromboembol
diseas
hemolyt
anemia
anaphylaxi
despit
lack
direct
comparison
convalesc
plasma
appear
promis
antiinfluenza
antibodi
therapi
particularli
pandem
scenario
due
novel
influenza
strain
ivig
lack
specif
influenza
hivig
timeconsum
product
may
limit
util
pandem
influenza
outbreak
nonetheless
signific
hurdl
remain
limit
clinic
outcom
data
method
mass
product
commerci
potenti
limit
convalesc
plasma
abil
widespread
use
current
product
must
outsourc
specialti
biomed
laboratori
highli
depend
upon
avail
will
donor
due
propens
sever
pulmonari
inflamm
respiratori
decompens
influenza
diseas
corticosteroid
suggest
confer
immunomodulatori
benefit
sever
studi
evalu
corticosteroid
influenza
diseas
without
promis
result
martinloech
et
al
perform
prospect
observ
studi
pandem
evalu
corticosteroid
use
patient
admit
icu
approxim
requir
mechan
ventil
nearli
third
die
icu
patient
receiv
steroid
like
die
icu
vs
p
b
howev
older
like
prior
pulmonari
diseas
despit
adjust
analys
reveal
differ
mortal
though
rate
hospitalacquir
pneumonia
higher
steroid
recipi
p
b
anoth
studi
pandem
brunbuisson
et
al
show
clinic
benefit
steroid
use
popul
ard
icuacquir
pneumonia
nearli
doubl
steroid
recipi
vs
p
furthermor
kim
et
al
also
found
higher
rate
superinfect
steroid
recipi
pandem
final
cohort
hospit
patient
infect
lee
et
al
found
corticosteroid
associ
delay
viral
clearanc
adjust
ci
strikingli
mani
studi
evalu
effect
corticosteroid
found
increas
risk
death
use
even
adjust
confound
factor
overal
corticosteroid
influenza
diseas
lack
clinic
benefit
appear
detriment
use
discourag
host
immun
respons
influenza
infect
may
play
critic
role
diseas
sever
proinflammatori
cytokin
interleukin
tumornecrosi
factor
highli
express
mediat
tissu
inflamm
contribut
increas
diseas
sever
poor
outcom
macrolid
known
possess
antiinflammatori
properti
may
abl
allevi
symptom
improv
outcom
patient
proinflammatori
diseas
influenza
studi
hospit
patient
mainli
infect
evalu
antiinflammatori
effect
azithromycin
combin
oseltamivir
compar
oseltamivir
alon
patient
receiv
azithromycin
signific
antiinflammatori
effect
note
support
addit
trial
evalu
clinic
benefit
openlabel
clinic
trial
random
treatment
group
assign
hong
kong
compar
threedrug
combin
clarithromycinnaproxenoseltamivir
oseltamivir
alon
hospit
patient
influenza
experiment
group
n
clarithromycin
mg
naproxen
mg
oseltamivir
mg
given
twice
daili
follow
oseltamivir
mg
twice
daili
addit
three
day
control
group
n
receiv
oseltamivir
mg
twice
daili
day
patient
also
receiv
g
amoxicillinclavulan
twice
daili
day
primari
outcom
mortal
median
age
approxim
year
patient
appear
sever
diseas
requir
invas
noninvas
ventil
hospit
patient
admit
icu
nevertheless
mortal
reduc
experiment
group
vs
p
experiment
therapi
independ
factor
associ
lower
mortal
multivari
analys
find
clinic
trial
certainli
interest
howev
unknown
therapi
would
benefici
sicker
popul
patient
differ
influenza
strain
addit
use
naproxen
may
rel
contraind
critic
patient
alreadi
high
risk
acut
kidney
injuri
use
macrolidebas
treatment
examin
secondari
analysi
prospect
observ
studi
critic
ill
patient
influenza
conduct
spain
pandem
need
antibiot
therapi
discret
treat
physician
primari
viral
pneumonia
present
patient
patient
administ
macrolid
usual
combin
antimicrobi
agent
clarithromycin
util
patient
azithromycin
patient
erythromycin
one
patient
patient
receiv
macrolid
n
patient
receiv
doubl
combin
antibiot
therapi
receiv
tripl
combin
therapi
overal
icu
mortal
lower
patient
receiv
macrolid
compar
vs
p
logist
regress
analysi
control
apach
ii
score
potenti
confound
factor
macrolid
use
associ
signific
reduct
mortal
ci
similar
result
obtain
subgroup
patient
mechan
ventil
result
suggest
benefit
macrolid
treatment
critic
ill
patient
primari
viral
pneumonia
due
time
lack
strong
compel
data
suggest
initi
macrolid
antibiot
improv
outcom
patient
influenza
howev
therapi
may
frequent
util
patient
concomit
pneumonia
immun
system
cascad
activ
respons
influenza
infect
may
potenti
therapeut
target
wang
et
al
suggest
mammalian
target
rapamycin
mtor
inhibitor
may
inhibit
cell
activ
provid
protect
effect
term
cytokin
storm
induc
viru
author
perform
openlabel
prospect
trial
wherein
patient
pcrconfirm
influenza
respiratori
support
requir
mechan
ventil
n
random
standard
oseltamivir
therapi
without
sirolimu
mgday
group
also
receiv
corticosteroid
standard
mgday
dose
prednisolon
found
favor
pao
fio
day
quicker
liber
mechan
ventil
among
sirolimu
recipi
sirolimu
recipi
also
greater
proport
patient
neg
repeat
pcr
day
vs
p
b
howev
quantit
assess
perform
differ
need
ecmo
death
observ
given
undesir
advers
effect
includ
cytopenia
renal
injuri
among
other
robust
studi
need
perform
substanti
find
prior
widespread
use
despit
high
mortal
initi
conceiv
ecmo
adjunct
therapi
sever
influenza
diseas
skyrocket
pandem
due
sever
respiratori
failur
refractori
hypoxemia
ecmo
may
augment
respiratori
effort
allow
abil
lung
recoveri
treatment
influenza
diseas
use
across
australia
new
zealand
southernhemispher
winter
pandem
describ
ecmo
recipi
young
healthi
baselin
minim
comorbid
prior
ecmo
initi
recipi
sever
ill
lowest
median
pao
fio
ratio
highest
median
paco
mmhg
median
acut
lung
injuri
score
receiv
ecmo
spent
nearli
twice
long
mechan
ventil
vs
p
b
icu
vs
p
b
twice
like
expir
icu
vs
p
compar
mechan
ventil
without
ecmo
despit
high
sever
ill
influenza
acut
respiratori
distress
syndrom
ecmo
recipi
mortal
rate
report
unit
kingdom
northernhemispher
pandem
describ
cohort
patient
refer
ecmo
similar
baselin
demograph
slightli
higher
sever
ill
margin
greater
use
vasoact
support
renal
replac
modal
ecmo
recipi
mortal
modestli
higher
howev
propensitymatch
nonecmo
patient
ecmo
recipi
less
like
die
vs
p
similarli
subsequ
metaanalysi
found
overal
randomeffect
pool
mortal
rate
across
studi
ecmo
recipi
contrarili
recent
studi
found
higher
similar
mortal
rate
propensitymatch
ecmo
recipi
nonrecipi
vs
p
overal
ecmo
experi
sever
influenza
diseas
appear
greatest
among
young
otherwis
healthi
popul
manifest
sever
diseas
inform
avail
regard
optim
time
cannul
ecmo
appear
viabl
salvag
therapi
patient
suffer
sever
influenza
ill
refractori
hypoxemia
particularli
pandem
scenario
influenza
signific
sourc
morbid
mortal
icu
much
care
provid
support
natur
howev
evid
suggest
earli
use
neuraminidas
inhibitor
nai
may
associ
mortal
reduct
critic
ill
patient
strategi
enhanc
nai
perform
includ
use
doubl
dose
oseltamivir
develop
altern
agent
intraven
peramivir
fail
show
benefit
icu
popul
immun
modul
therapi
shown
promis
limit
avail
evid
agent
may
particularli
use
pandem
scenario
due
novel
influenza
strain
specif
patient
fail
improv
despit
standard
therapi
escal
respiratori
support
howev
larger
scale
random
control
trial
therapi
optim
manufactur
process
commerci
product
necessari
success
widespread
applic
